Why ex vivo CAR T still matters in the age of in vivo hype As in vivo CAR T gains momentum, developers are finding new ways to make ex vivo manufacturing faster, more reproducible, and scalable. Written byBree Foster, PhD

Why ex vivo CAR T still matters in the age of in vivo hype As in vivo CAR T gains momentum, developers are finding new ways to make ex vivo manufacturing faster, more reproducible, and scalable. Written byBree Foster, PhD https://www.drugdiscoverynews.com/why-ex-vivo-car-t-still-matters-in-the-age-of-in-vivo-hype-17472 The promise of in vivo CAR T is easy to understand. Instead of removing a patient's cells, engineering them in a manufacturing facility, and returning them to the body, developers are working toward delivering the machinery needed to create CAR T cells directly inside the patient. When a failed trial isn't a failed drug A new AI analysis of a negative Alzheimer's trial raises questions about whether conventional clinical trials are missing patients who could still benefit from treatment. Written byBree Foster, PhD https://www.drugdiscoverynews.com/when-a-failed-trial-isn-t-a-failed-drug-17431?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz--9ymqQTeCqXvQSBNk7-mYIIpdJ6DdkuW3H9ORbkurEIa22v0ufhux8-JXQ-vFQ0uGpbRArvqIeh6orNmzAn-f5FdmOHg&_hsmi=434389976&utm_content=434389976&utm_source=hs_email When a Phase 3 clinical trial misses its primary endpoint, the outcome is often treated as definitive. The drug failed to demonstrate efficacy, development stops, and the therapy may never be tested again. But a negative trial in a heterogeneous patient population does not necessarily mean that every participant failed to benefit. It may instead mean that any treatment effect was diluted when patients with very different disease biology and treatment responses were analyzed together.